Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam

Epilepsia

Volumn 50, Issue 3, 2009, Pages 387-397

  Kaminski, Rafal M ^a,b   Matagne, Alain ^b   Patsalos, Philip N ^c   Klitgaard, Henrik ^b  

^a UCB   (Belgium)

^b Preclinical CNS Research   (Belgium)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Levetiracetam, Antiepileptic drugs, Drug interactions, Epilepsy, Animal models

Indexed keywords

1 [2 (BENZHYDRYLIDENEAMINOOXY)ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE; BRETAZENIL; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; DIZOCILPINE; ETIRACETAM; FELBAMATE; FLUNARIZINE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; AUDIOGENIC SEIZURE; CLONIC SEIZURE; CONVULSION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EPILEPSY; FOCAL EPILEPSY; HUMAN; KINDLING; MONOTHERAPY; MOUSE; NEUROTRANSMISSION; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PIRACETAM;

EID: 61849098715     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01713.x     Document Type: Article

References (72)

1. 2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport 14 : 471 475.
2. Barton ME, Klein BD, Wolf HH, White HS 2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47 : 217 227.
3. Ben Menachem E, Falter U 2000) Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 : 1276 1283.
4. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U 2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69 : 1751 1760.
5. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stöhr T 2007) Lacosamide: a review of preclinical properties. CNS Drug Rev 13 : 21 42.
6. Bouwman BM, van Rijn CM 2004) Effects of levetiracetam on spike and wave discharges in WAG/Rij rats. Seizure 13 : 591 594.
7. Brodie MJ, Perucca E, Ryvlin P, Ben Menachem E, Meencke HJ 2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 : 402 408.
8. Coupez R, Nicolas JM, Browne TR 2003) Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 44 : 171 178.
9. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM 1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 96 : 15268 15273.
10. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM 2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26 : 1303 1313.
11. Czuczwar SJ, Borowicz KK 2002) Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 52 : 15 23.
12. De Smedt T, Raedt R, Vonck K, Boon P 2007) Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 13 : 57 78.
13. Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, van Rijn CM 2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41 : 1364 1374.
14. Donato Di Paola E, Gareri P, Davoli A, Gratteri S, Scicchitano F, Naccari C, De Sarro G 2007) Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. Epilepsy Res 75 : 112 121.
15. Gasior M, Carter RB, Goldberg SR, Witkin JM 1997) Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther 282 : 543 553.
16. Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E 1992) ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 222 : 193 203.
17. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C 1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22 : 207 213.
18. Iadarola MJ, Gale K 1982) Substantia nigra: site of anticonvulsant activity mediated by gamma-aminobutyric acid. Science 218 : 1237 1240.
19. 2+ regulators in neurotransmitter release. Neuron 24 : 1003 1016.
20. Jonker DM, Voskuyl RA, Danhof M 2007) Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 48 : 412 434.
21. Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H 2008) SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54 : 715 720.
22. Klitgaard H, Knudsen ML, Jackson HC 1993) Synergism between drugs with diffrent mechanisms of action against audiogenic seizures in DBA/2 mice. Epilepsia 34 (Suppl. 6 93 94.
23. Klitgaard H, Matagne A, Gobert J, Wülfert E 1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353 : 191 206.
24. Klitgaard H 2001) Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 42 (Suppl. 4 13 18.
25. Klitgaard H, Matagne A 2002) Levetiracetam enhances markedly the seizure suppression of other antiepileptic drugs in amygdala-kindled rats. Epilepsia 43 (Suppl. 7 219.
26. Klitgaard H, Matagne A, Grimee R, Vanneste-Goemaere J, Margineanu DG 2003) Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure 12 : 92 100.
27. Kwan P, Brodie MJ 2006) Combination therapy in epilepsy: when and what to use. Drugs 66 : 1817 1829.
28. Löscher W, Honack D 1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232 : 147 158.
29. Löscher W, Rundfeldt C, Honack D 1993) Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur J Neurosci 5 : 1545 1550.
30. Löscher W, Honack D 1994) Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur J Pharmacol 259 : R3 R5.
31. Löscher W, Wauquier A. (1996) Use of animal models in developing guiding principles for polypharmacy in epilepsy. In Homan RW, Leppik IE, Lothman EW, Penry JK, Theodore WH (eds) Rational Polypharmacy; Epilepsy Research Supplements 11, Elsevier, Amsterdam, pp. 61-65.
32. Löscher W, Honack D, Bloms-Funke P 1996) The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 735 : 208 216.
33. Löscher W 1998) New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 342 : 1 13.
34. Löscher W, Honack D, Rundfeldt C 1998) Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284 : 474 479.
35. Löscher W 1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58 : 31 59.
36. Luszczki JJ, Czuczwar SJ 2003) Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. Epilepsy Res 56 : 27 42.
37. Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Wojcik-Cwikla J, Ratnaraj N, Patsalos PN, Czuczwar SJ 2005) Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol 15 : 609 616.
38. Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Ratnaraj N, Patsalos PN, Czuczwar SJ 2006) Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 47 : 10 20.
39. Luszczki JJ, Andres-Mach MM, Ratnaraj N, Patsalos PN, Czuczwar SJ 2007) Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 48 : 806 815.
40. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B 2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101 : 9861 9866.
41. Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann EJ 2003) Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 45 : 661 671.
42. Matagne AC, Baltes E, Coupez R, Patsalos PN, Klitgaard HV 2001) Levetiracetam enhances markedly the seizure suppression of other antiepileptic drugs in audiogenic susceptible mice. Epilepsia 42 (Suppl 7 82.
43. Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG 2004) Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 58 : 167 174.
44. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, DeLorey TM, Olsen RW, Homanics GE 1999) Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA 96 : 12905 12910.
45. Moulder KL, Mennerick S 2005) Reluctant vesicles contribute to the total readily releasable pool in glutamatergic hippocampal neurons. J Neurosci 25 : 3842 3850.
46. Moulder KL, Mennerick S 2006) Synaptic vesicles: turning reluctance into action. Neuroscientist 12 : 11 15.
47. Moulder KL, Jiang X, Taylor AA, Shin W, Gillis KD, Mennerick S 2007) Vesicle pool heterogeneity at hippocampal glutamate and GABA synapses. J Neurosci 27 : 9846 9854.
48. Nagarkatti N, Deshpande LS, Delorenzo RJ 2008) Levetiracetam Inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett 436:289-293.
49. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 306 : 5 8.
50. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J, N166 Levetiracetam Study Group 2008) The N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70 : 607 616.
51. Noyer M, Gillard M, Matagne A, Henichart JP, Wulfert E 1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286 : 137 146.
52. Nusser Z, Mody I 2002) Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. J Neurophysiol 87 : 2624 2628.
53. Palma E, Ragozzino D, Angelantonio SD, Mascia A, Maiolino F, Manfredi M, Cantore G, Esposito V, Di Gennaro G, Quarato P, Miledi R, Eusebi F 2007) The antiepileptic drug levetiracetam stabilizes the human epileptic GABA(A) receptors upon repetitive activation. Epilepsia 48 : 1842 1849.
54. Patsalos PN 2000) Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85 : 77 85.
55. Patsalos PN, Froscher W, Pisani F, van Rijn CM 2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43 : 365 385.
56. Patsalos PN 2004) Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother 13 : 1 168.
57. Perucca E, French J, Bialer M 2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6 : 793 804.
58. A antagonists in hypothalamic neurones. Neuropharmacology 42 : 346 352.
59. Reynolds EH, Shorvon SD 1981) Monotherapy or polytherapy for epilepsy? Epilepsia 22 : 1-10.
60. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H 2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal. Br J Pharmacol 136 : 659 672.
61. Rogawski MA 2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69 : 273 294.
62. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P 2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41 : 1179 1186.
63. A receptor subtypes. Adv Pharmacol 54 : 231 263.
64. Sills GJ, Butler E, Thompson GG, Brodie MJ 2004) Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure 13 : 287 295.
65. A receptors. Proc Natl Acad Sci U S A 100 : 14439 14444.
66. Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White HS 2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74 : 147 154.
67. Tallarida RJ 2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298 : 865 872.
68. Turski L, Cavalheiro EA, Turski WA, Meldrum BS 1986) Excitatory neurotransmission within substantia nigra pars reticulata regulates threshold for seizures produced by pilocarpine in rats: effects of intranigral 2-amino-7-phosphonoheptanoate and N-methyl-D-aspartate. Neuroscience 18 : 61 77.
69. Urbanska E, Dziki M, Kleinrok Z, Czuczwar SJ, Turski WA 1991) Influence of MK-801 on the anticonvulsant activity of antiepileptics. Eur J Pharmacol 200 : 277 282.
70. Wu Y, Wang W, Richerson GB 2001) GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter. J Neurosci 21 : 2630 2639.
71. Xu T, Bajjalieh SM 2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3 : 691 698.
72. Zarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ 1993) 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology 32 : 895 900.